SARTORIUS STEDIM, DEAR TO THE CORE (SELL; -29% DOWNSIDE)
23/02/21 -" Sartorius Stedim Biotech (Sell, France) ranks as a top-notch asset, with industry-leading return metrics (FY20 ROE of 26% vs 14% for AV peers). Since we noted its phenomenal run almost two years ..."
Pages
61
Language
English
Published on
23/02/21
You may also be interested by these reports :
05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...
05/02/26
Our estimates have been moderated following the Q4 25 miss, primarily reflecting a softer order book and growth momentum (especially for the LS ...
05/02/26
Siemens Healthineers’ Q1 profitability exceeded the company-compiled consensus. While sales rose in Q1, growth was limited due to weakness in China. ...
04/02/26
The FY25 performance was in line with expectations, with 7.6% revenue growth and 170bps margin expansion driven by BPS strength, improved mix, and ...